Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Core Insights - Lexaria Bioscience Corp. has extended its Material Transfer Agreement (MTA) with PharmaCO until April 30, 2026, to allow for the review of data from an Australian study [2][3] - The MTA enables continued collaboration and strategic planning discussions between Lexaria and PharmaCO's clinical development team [2] - Lexaria's DehydraTECH™ technology aims to enhance drug delivery through oral administration, improving bio-absorption and reducing side effects [4] Summary by Sections Material Transfer Agreement Update - The MTA originally signed on September 4, 2024, has been extended to accommodate PharmaCO's review of Lexaria's Australian study data [2] - This extension allows both parties to maintain their relationship and keep the temporary exclusive license active [2] Pre-Clinical Studies and Future Expectations - Initial pre-clinical studies examining pharmacokinetics in animals have been completed [3] - Lexaria is awaiting PharmaCO's review of safety, pharmacokinetic, and efficacy data from its independent Australian human clinical study, with final results expected by the end of Q4 2025 [3] About Lexaria and DehydraTECH - DehydraTECH™ is a patented drug delivery platform that enhances the absorption of various drugs through oral delivery [4] - Lexaria holds a strong intellectual property portfolio with 54 patents granted and additional patents pending globally [4]